Insulin-regulated glucose uptake in rat adipocytes is mediated by two transporter isoforms present in at least two vesicle populations.
We have recently described a monoclonal antibody (1F8) that recognizes a form of glucose transporter unique to fat and muscle (James, D. E., Brown, R., Navarro, J., and Pilch, P. F. (1988) Nature 333, 183-185), tissues that respond acutely to insulin by markedly increasing their glucose uptake. Here, we report that rat adipocytes possess two immunologically distinct glucose-transporters: one recognized by 1F8, and one reactive with antibodies raised against the human erythrocyte glucose transporter. Immunoadsorption experiments indicate that these glucose transporters reside in different vesicle populations and that both transporter isoforms translocate from intracellular sites to the plasma membrane in response to insulin. The insulin-regulatable transporter resides in a unique vesicle that comprises 3% or less of the low density microsomes of fat cells and has a limited protein composition that does not include the bulk of another translocatable protein, the insulin-like growth factor II receptor. Immunoprecipitation with 1F8 of microsomal glucose transporters photoaffinity labeled with [3H]cytochalasin B brings down 90% of the label. Similarly, immunoprecipitation with 1F8 of glucose transporters from insulin-stimulated plasma membranes photolabeled with 3-[125I]iodo-4-azidophenethylamido-7-O-succinyldeacetyl-f ors kolin, another transporter-selective reagent, results in 75% of the labeled transporter localized in the immunoprecipitate. Thus, insulin action involves the combined effect of translocation from at least two vesicle pools each containing different glucose transporters. The 1F8-reactive transporter comprises the majority of the total transporter pool that is responsible for the insulin-induced increase in glucose transporter number.
Zorzano
A
A
Department of Biochemistry, Boston University School of Medicine, Massachusetts 02118.
Wilkinson
W
W
Kotliar
N
N
Thoidis
G
G
Wadzinkski
B E
BE
Ruoho
A E
AE
Pilch
P F
PF
D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism*; D000345:Affinity Labels / Q000378:metabolism; D000818:Animals; D001386:Azides / Q000378:metabolism; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D002478:Cells, Cultured; D005576:Colforsin / Q000031:analogs & derivatives / Q000378:metabolism; D003571:Cytochalasin B / Q000378:metabolism; D004224:Diterpenes; D005947:Glucose / Q000378:metabolism*; D007328:Insulin / Q000494:pharmacology*; D007335:Insulin-Like Growth Factor II / Q000378:metabolism; D008297:Male; D009004:Monosaccharide Transport Proteins / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D011956:Receptors, Cell Surface / Q000378:metabolism; D017451:Receptors, Somatomedin
D000345:Affinity Labels; D001386:Azides; D004224:Diterpenes; D007328:Insulin; D009004:Monosaccharide Transport Proteins; D011956:Receptors, Cell Surface; D017451:Receptors, Somatomedin; C054433:3-iodo-4-azidophenethylamido-7-O-succinyldeacetylforskolin; D005576:Colforsin; D003571:Cytochalasin B; D007335:Insulin-Like Growth Factor II; D005947:Glucose